MREO Mereo Biopharma

$MREO no reverse split risk till late Feb 27. Funds into late 2027 Two major catalysts ahead and in this year. Penny stock with cash and catalysts

$MREO my first target is this extremely large gap that needs to fill. Good news like today, volume, or valuation correction will fill this. Or just unfollow me. I bring you these perfect monster setups.

$MREO If you look at the 1.5W chart, you can clearly see that someone has been quietly and gradually accumulating shares, largely under the radar. Either short positions are being closed now, or someone is going heavily long! I suspect the rumors surrounding Syntnl might actually be true. $KOD $RARE

$MREO Rubrics valuation for Setrusumab only in 2022. IMHO nothing has changed. I think Alvelestat alone is worth more than 4 $

$MREO approaching the 200sma. Let’s break through and let the rest of the moving averages follow with a good pop. 👍🤞🚀

$MREO I think someone knows more than we do and has been quietly accumulating shares over the past week, deliberately keeping the purchases slow and discreet so the price doesn’t immediately explode.

$MREO short interest down another 500k with only 2,6M shares shorted and this loses 15% less than 2 session ahead of data read tomorrow and getting closer to option exercise and news from FDA 🤯🤯🤯

$MREO This is purely because of the stock—many people are going to be kicking themselves in the coming weeks for not getting in early enough. Remember my words.

$MREO $3 PT per TipRanks analysts and a few catalysts in play. DYOR!! You can have my shares for $2 fiddy!! 🚀

$MREO This time it's gonna be hard to take profits because we could be on the verge of something huge. Something has definitely changed so it's very possible for this to pop overnight and before you can get back in. I think I'll hold! GL

$MREO i always like when im the only one loading. Then i repost these all later. They will find this in the gap and run it back above $2…. On just valuation correction, or if they actually read the new data and watched the presentation. This is what i talk about alot when they are sleeping. Theyneverlisten ……………….. ever

$MREO had a strong week, moving from ~$0.29 to $0.34–0.35. I’m cautious: without concrete positive catalysts, it could remain in the $0.27–$0.35 range. Is this simply positioning ahead of Sentynl/Alvelestat and Setrusumab, or does the market already know something we don’t? Any concrete information behind the move?

$MREO Two weeks left until Ultragenyx Q3 conference call, most probably with an update on FDA interactions and strategic priority of Setrusumab. In addition, 12 month follow up data could be shared. Mereo Q3 conference call the week after, hopefully with update on FDA interaction on Alvelestat endpoints and short term opt-in by Sentynl. Lot‘s of catalyst on the horizon, I take the chance and keep loading.

$MREO wait until all the big players find it down here. 👇 loading under .40 is crazy. When it hits the scanners they will send it.. with or without news. Zero chase so far … its being loaded.

$MREO Is Rubric Capital Management is the largest shareholder of MREO? They were angry on them in 2022 If they are still holding that means they still believe here? Any longs here?

$MREO Calm down, everyone—this isn't going to take off like a spaceship just because it looks like one... If you look at it today, the ROCKET is falling at a high speed.

$MREO So I'd like to know where, you got the notion Said I'd like to know where, you got the notion (To rock the boat), don't rock the boat baby , don't tip the boat over (Rock the boat), don't rock the boat baby (Rock the boat)

$MREO I’m glad I sold all my Mereo BioPharma shares last week 🙂 Something just didn’t feel right in the end. But I still believe in the stock’s potential.

$MREO I just reminded myself When Rubric Capital first took a position in Mereo. Rubric Capital Management LP first crossed the 5% regulatory threshold and officially initiated its activist position in Mereo BioPharma Group plc (MREO) on May 26, 2022, which is when they filed their initial Schedule 13D with the SEC. Historical Context & Estimated Entry Price • The 13D Filing Date: May 26, 2022. • Stock Price at Initiation: In May 2022, MREO was trading in a deeply depressed range, fluctuating roughly between $0.40 and $0.80 per share. • The Activist Push: Rubric initially built the position because they believed the company was massively undervalued. Shortly after filing, they launched a public proxy campaign in August 2022 to restructure Mereo's board, eventually reaching a board cooperation agreement in October 2022.

$MREO This may be a day when investors average up. Volume is up but not yet explosive. GL